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AbstrAct
Although less frequent than vascular calcification, 
cardiac valve calcification (CVC) is a relevant clini-
cal problem affecting about 2%-10% of adults from 
the general population aged 75 years and older, and 
is 5- to 10-fold more prevalent in individuals with 
impaired kidney function. An expanding body of evi-
dence suggests that mineral metabolism abnormali-
ties aside from traditional cardiovascular risk factors 
are involved in CVC pathogenesis. Nonetheless, very 
few studies have investigated whether mineral me-
tabolism manipulation impacts CVC. In this issue of 
the Journal of Nephrology, it is reported that a com-
bination of low-phosphate diet and sevelamer may 
reduce CVC. Though the observational nature of that 
study and the lack of a control group significantly 
limit the generalizability of these results, they fit in 
with the ongoing debate on the role of chronic kidney 
disease mineral bone metabolism (CKD-MBD) in the 
pathogenesis of vascular disease and suggest the 
importance of mineral metabolism control in patients 
with CKD. 
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prevalence is reported in age- and sex-matched individuals 
with impaired kidney function (1, 5, 6).
Although the pathologic mechanisms are only partially 
understood (7), some evidence suggests that heart valvu-
lar calcification shares similar risk factors and pathoge-
netic features with atherosclerosis (older age, male sex, 
hypertension, smoking, hypercholesterolemia and dia-
betes) (8). However, mineral bone metabolism and other 
nontraditional cardiovascular (CV) risk factors have also 
been shown to be involved (6, 9, 10) and may partially 
explain why as many as 50% of subjects from the general 
population with valvular calcification do not have clinically 
meaningful atherosclerosis (11), and why the risk of car-
diac valve calcification increases as glomerular filtration 
(GFR) declines (5, 9). In particular, observational studies 
suggest a strong and independent association between 
serum phosphorous levels and the risk of valve calcifi-
cation (6). In the Multi-Ethnic Study of Atherosclerosis, 
serum phosphorus levels were associated with aortic and 
mitral valve calcification in a cohort of 439 subjects with 
mild-to-moderate CKD (mean estimated GFR [eGFR] 
about 50 ml/min per 1.73 m2) (6). Each 1 mg/dL increase 
in serum phosphate corresponded to a significant 25% 
and 62% greater prevalence of aortic valve and mitral 
valve calcification, respectively (6). Notably, adjustment 
for eGFR, age and other parameters of mineral metabo-
lism did not substantially affect these associations, which 
were significant even for serum phosphate levels within 
the reference range (6). 
Irrespective of the pathogenesis, heart valve calcifications 
predict poor survival in both the general and the CKD 
population (2, 3, 10, 12, 13). Indeed, calcified valves have 
Although less frequent than vascular calcification, cardiac 
valve calcification is a relevant clinical problem in the gen-
eral population as well as in patients with chronic kidney 
disease (CKD) (1-3). It is estimated that about 2%-10% of 
adults 75 years of age and older exhibit aortic and mitral 
valve calcification (3, 4). A significant 5- to 10-fold greater 
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been associated with extensive calcification burden in the 
coronary arteries (1, 14), carotid atherosclerosis and cal-
cification (15), progressive valve narrowing, left ventricu-
lar hypertrophy and heart failure (10, 16). In a group of 
140 transplant candidates with late stages of CKD or on 
maintenance dialysis, evidence of calcified mitral annulus 
was significantly associated with left atrial and ventricular 
enlargement, cardiac mass index, left ventricular diastolic 
dysfunction and mortality (10). In a series of 144 prevalent 
end-stage renal disease (ESRD) patients, the presence 
and the extension of aortic and mitral valve calcification 
assessed via cardiac computed tomography (CT) predict-
ed the risk of all-cause mortality independently of several 
confounders. Notably, a combined CT score of valvular 
and coronary artery calcification (CAC) was strongly as-
sociated with all-cause mortality during follow-up (hazard 
ratio for highest vs. lowest tertile, 2.21; 95% confidence 
interval, 1.08-4.54) (2). 
Due to the fact that the underlying pathophysiology remains 
incompletely defined and there is a lack of effective medical 
treatments capable of altering the natural course of cardiac 
valve calcification, whether aortic or mitral valve calcifica-
tions represent a marker or a promoter of CV disease still 
needs to be elucidated. Nonetheless, in light of how easy it 
is to make a cardiac valve calcification assessment, this in-
formation could be of use in risk stratification and potentially 
to guide treatment individualization (17). 
In this regard, in the current issue of the Journal of 
Nephrology an interesting observation is reported. In a 
single-center, single-arm, prospective study, the impact 
on valvular calcification of sevelamer HCl in combination 
with a low-protein diet was tested in 160 consecutive 
CKD stage 3 and 4 patients. Of note, all recruited subjects 
at study inception had evidence of either mitral or aortic 
valve calcification as well as suboptimal serum phosphate 
control with median levels of 4.9 mg/dL (interquartile 
range 4.7-5.2). After 12 months of treatment, a significant 
reduction in aortic and mitral valve calcification burden as 
assessed via a semiquantitative echocardiographic score 
was noted. This finding was coupled with a significant 
reduction in phosphate balance as demonstrated by the 
lower levels of serum fibroblast growth factor 23 (FGF-
23) and phosphate as well as 24-hour urinary phosphate 
excretion.
Though the lack of a control group and the observational 
nature of the study preclude definitive causal conclusions, 
these results further corroborate the hypothesis that 
phosphorous and mineral metabolism manipulation may 
represent a potential therapeutic target in CKD patients 
with evidence of CV calcification (17). 
Two other studies have investigated the impact of different 
agents of valvular calcification progression. In a post hoc 
analysis of the Treat to Goal study (18), Raggi and cowork-
ers observed in a cohort of 132 prevalent hemodialysis pa-
tients that 52 weeks of sevelamer HCl use was associated 
with a significant attenuation of cardiac calcification when 
compared with calcium salts (18). In particular, the authors 
reported a significantly greater number of sevelamer-treated 
subjects experiencing an arrest (45% vs. 28%, p = 0.04) or 
regression (26% vs. 10%, p = 0.02) in total valvular and vas-
cular calcification (18). In a more recent study, the impact 
of cinacalcet plus low-dose vitamin D vs. flexible doses of 
vitamin D, on cardiac calcification was tested (19). As high-
lighted in a subsequent post hoc analysis, prevalent hemo-
dialysis subjects with evidence of aortic valve calcification 
were likely to benefit from the combined treatment with cina-
calcet and low doses of vitamin D and experience significant 
cardiac valve calcification progression attenuation (20).
Hence, there is evidence supporting the notion that mineral 
metabolism is implicated in the pathogenesis of vascular 
calcification. The current article adds to the existing body 
of evidence suggesting that a precocious intervention (i.e., 
at CKD stage 3B) aimed at lowering of phosphate balance 
could result in CV disease reduction in CKD. When and how 
to correct these abnormalities in the course of CKD still 
remains debatable (21, 22). Observational data support the 
notion that the risk of cardiac calcification (6) as well as CV 
death (23) and all-cause mortality (23) is increased for serum 
phosphate within the reference range. Nonetheless, we 
currently lack a validated marker of phosphate metabolism 
imbalance to discriminate those individuals at increased 
risk for CV events. Indeed, phosphaturia and phosphoremia 
(with the exceptions of extreme levels) only weakly correlate 
with phosphate balance, and newer markers such as FGF-
23) (24) or Klotho are not routinely assessed (21). Far more 
importantly, the complicated interplay of different factors 
modulates the risk to which an individual is exposed (25). 
In a large cohort of 872 subjects recruited in the Heart and 
Soul study, phosphaturia modulated the risk associated with 
high phosphate balance (25). Individuals with high levels of 
FGF-23 but preserved phosphaturic response experienced 
a lower risk of both all-cause mortality and CV events when 
compared with individuals with high FGF-23 and low urinary 
phosphate output (25). 
In light of the findings that complete FGF-23 neutraliza-
tion is associated with increased risk of death in an ani-
mal model (26), it is plausible that phosphate balance is 
far more important than serum phosphate per se, showing 
that phosphate dampening is, to a certain degree, an adap-
tive mechanism to prevent phosphorous accumulation (27). 
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These hypotheses may potentially explain the surprising 
results of 2 recent randomized controlled trials that have 
failed to show a positive effect of sevelamer carbonate vs. 
placebo on cardiac mass (28), arterial stiffness (28), left 
ventricular function (28) and CAC (29) in mild-to-moderate 
CKD with normal serum levels. Aside from study design 
differences (21), these results are in contrast to previous 
findings that showed a significant improvement associated 
with sevelamer use, with regard to endothelial function (30, 
31), CAC (32) and survival (32) in moderate CKD individuals 
with hyperphosphatemia. However, as in the study present-
ed in this issue of the Journal of Nephrology (33), the inclu-
sion of individuals with overt hyperphosphatemia may have 
selected those individuals with more severe phosphorous 
imbalances, uncompensated by phosphaturic hormones 
and likely more susceptible to phosphate-lowering inter-
ventions. Finally, the use of calcium-containing phosphate 
binders instead of placebo may also contribute to explain-
ing these results (34). Indeed, a growing body of evidence 
suggests a detrimental effect of calcium supplementation 
in normal kidney function subjects (35-37), enhanced posi-
tive calcium balance (38) in CKD and a potential for FGF-
23 increase (39) that in turn worsens mineral metabolism 
homeostasis. 
In summary, current results fit in with the ongoing debated 
on the role of chronic kidney disease mineral bone metabo-
lism (CKD-MBD) in the pathogenesis of vascular disease in 
CKD. In light of the noninvasive and inexpensive techniques 
available to screen for valvular calcification, future research 
should test, in a prospective and randomized study, whether 
sevelamer and a low-phosphate diet can attenuate or re-
verse valvular calcification, and whether this intervention 
improves CKD patients’ survival.
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